Putting patients first,
is at the heart of what we do
Saving Lives in Resistant Times: BioVersys' mission to provide lifesaving medicines and address the Antimicrobial Resistance crisis.
At BioVersys, we are fully aware of the urgent nature of our mission. We are leading the charge against antimicrobial resistance (AMR), to provide patient oriented solutions in the fight against life-threatening bacterial infectious diseases. Recognized by esteemed global organizations like the World Health Organization (WHO), the G7, and the G20, AMR poses an imminent and present danger to our current way of life that could lead to an annual death toll greater than all cancers combined by 20501. Refusing to accept this future, we have embarked on an important journey to combat superbugs. We are targeting the most alarming pathogens, including Acinetobacter baumannii and Staphylococcus aureus, as identified by the WHO.
Antimicrobial Resistance
Our Commitment to Global Health
At BioVersys, we have embraced the challenge of developing novel antibiotic therapies through a diverse and de-risked pipeline strategy, with new mode of action (MoA) antimicrobials. Among our innovative assets is our BV100 program, targeting A. baumannii. BV100 shows exquisite activity against difficult to treat carbapenem-resistant Acinetobacter baumannii (CRAB) found in indications such as pneumonia and blood stream infections, where there are no or limited treatment options.
Tuberculosis
A new hope in the fight against tuberculosis, the world's largest infectious disease killer.
BioVersys has developed a novel anti-TB molecule, alpibectir (BVL-GSK098), with a unique mode of action that enhances the activity of the well-established drug ethionamide. This breakthrough approach is being assessed in human clinical trials, bringing new possibilites to patients and families affected by this deadly disease.
TB is a highly contagious and life-threatening disease caused Mycobacterium tuberculosis and remains a formidable global health challenge, with an estimated 1.3 million deaths in 2022. Despite its global impact, TB, especially MDR and XDR TB and TB meningitis still lack sufficient treatment options, leaving many patients without effective medicines.
Our pioneering efforts have led to the clinical validation of a new class of bacterial targets and the development of the novel anti-TB molecule alpibectir, now in Phase 2a clinical trials after 10 year of R&D with partners at the Pasteur Institute Lille, the University of Lille, GSK and with financial support from the Wellcome Trust and the European Union.
This breakthrough therapy utilizes a novel mode of action to overcome resistance, significantly enhancing the activity and increasing the safety through a lower-dose level of the well-established TB prodrug ethionamide - offering new hope and a treatment option for patients fighting this persistent and deadly disease.
Alipibectir and ethionamide both penetrate well into the cerebrospinal fluid (CSF) and can cross the blood brain barrier (BBB), offering the opportunity and hope to address TB meningitis (TBM), perhaps the deadliest form of TB, that affects children as well as some adults, with devastating life-long complications and high mortality rates (up to 50% in adults). Treatment options for TBM are extremely limited and inadequate due to the inability of most drugs to penetrate the CSF.
Discover the breakthrough advancements that are promising to reshape the landscape of TB treatment and join us on the journey towards a brighter, healthier future.
Patient stories
Pioneering Transformative Therapies to Empower Patients' Lives - The Essence of Our Mission from the Start.
At the heart of our mission is the goal of improving the lives of patients. Get to know some community heroes here.
We want to hear from you.
We are eager to hear from you. Contact us for more information.
Follow us on social media
